Search

Displaying results 3391 - 3400 of 8412 in total
  1. Drug

    Arbaclofen Placarbil

    go.drugbank.com/drugs/DB08892
    Investigational

    Arbaclofen Placerbil was believed to have therapeutic potential in treating gastroesophogeal reflux disease (GERD) and plasticity; however due to discouraging clinical trial results, the drug was abandoned … It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties.

  2. Drug

    INCB13739

    go.drugbank.com/drugs/DB05064
    Investigational

    It is an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears to be critical to the development of type 2 diabetes

  3. Drug

    Afimetoran

    go.drugbank.com/drugs/DB16580
    Investigational

    Afimetoran is an immunomodulator and an antagonist of toll-like receptors 7 and 8.

  4. Drug

    Galiximab

    go.drugbank.com/drugs/DB04901
    Investigational

    Galiximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.

  5. Drug

    Inonotus obliquus fruiting body

    go.drugbank.com/drugs/DB14332
    Approved

    It is not an approved drug.

  6. Drug

    Atractylodes lancea root oil

    go.drugbank.com/drugs/DB14338
    Approved

    It is not an approved drug.

  7. Drug

    WL-1002

    go.drugbank.com/drugs/DB05346
    Experimental

    WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin (also known as civamide), for the treatment of pain due to osteoarthritis.

  8. Drug

    Ombitasvir

    go.drugbank.com/drugs/DB09296
    ApprovedInvestigational

    Ombitasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly [FDA Label]. … Ombitasvir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  9. Drug

    Oxyphenisatin acetate

    go.drugbank.com/drugs/DB14627
    ApprovedWithdrawn

    The FDA withdrew its approval for the use of oxyphenisatin acetate due to safety reasons.[L43942]

  10. Drug

    Risankizumab

    go.drugbank.com/drugs/DB14762
    ApprovedInvestigational

    Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risan...